In my opinion, if AMGN does not seal the deal with ONXX, it will be penalized for lack of leadership and conviction. I see downgrades coming for AMGN from analyst who see AMGN/ONXX as a great strategic fit. It is all about leadership and now is the time it is being tested.
Good Point.Look at Gilead. It paid 11 billion$ for Pharmacett--a high risk drug for Hepititus( Inhibitex and Identix trials stopped by FDA ,but Pharmacett drug going ok with no significant liver damage.). Gilead stock has done well.
Amgen is in trouble with dismal growth over next 5 years. It needs to act like Gilead and buy Onyx.